Obese adult PCOS patients treated with MYO (2 g/day) and ALA (200 mg/di) for eight weeks showed decreased BMI, LH, LH/FSH ratio, androstenedione, and insulin levels, with the most significant results observed in obese insulin-resistant PCOS patients [94]. This evidence concerns the gene BRD2 and polycystic ovary syndrome.